Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of> 15 Years from the …
Background: Favorable acute myelogenous leukemia (AML) includes AML with t (8: 21), inv
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …
Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of> 15 Years from the …
A Nagler, M Labopin, U Salmenniemi, D Wu, D Blaise… - Blood, 2023 - ashpublications.org
Background: Favorable acute myelogenous leukemia (AML) includes AML with t (8: 21), inv
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …